← Search & browse all drugs
RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS › Other drugs for obstructive airway diseases, inhalants
ensifentrine
R03BX02
Forms & Strengths
- Inhalation suspension: 0.3 mg per 2 mL unit-dose ampule
Adult Dosing
- 0.3 mg administered twice daily (morning and evening) via standard jet nebulizer
Pediatric Dosing
- Safety and efficacy in pediatric patients below 18 years of age have not been established
Indications
- Maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults
Mechanism of Action
- Selective dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4)
- Exhibits both bronchodilatory (via PDE3 inhibition in airway smooth muscle) and anti-inflammatory (via PDE4 inhibition) activities
Contraindications
- Known hypersensitivity to ensifentrine or any of its formulation excipients
Adverse Reactions
- Back pain
- Nasopharyngitis
- Increased blood creatinine phosphokinase
- Diarrhea
- Urinary tract infection
Drug Interactions
- Strong CYP3A4 inhibitors may increase systemic exposure of ensifentrine
- Strong CYP3A4 inducers may decrease systemic exposure of ensifentrine
- Concomitant use with other PDE inhibitors should be approached with caution due to additive potential toxicities
Curated Content: Needs Vetting Before Put to Clinical Use